NDA 022047 · Cheplapharm
Seroquel Xr
Quetiapine Fumarate · Oral
Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
May 17, 2007
Approved uses
6
Original approval plus efficacy supplements
Registered trials
398
129 Phase 3, 13 recruiting
FAERS reports
166,283
129,383 serious, 22,401 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1 )] . SEROQUEL XR is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.2) ] ....
What it is approved for
From the label in effect Apr 10, 2026.
SEROQUEL XR is an atypical antipsychotic indicated for the treatment of: • Schizophrenia (1.1) • Bipolar I disorder, manic, or mixed episodes (1.2) • Bipolar disorder, depressive episodes (1.2) • Major depressive disorder, adjunctive therapy with antidepressants (1.3) 1.1 Schizophrenia SEROQUEL XR is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL XR in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. Efficacy was supported by three 6-week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia (13-17 years) treated with SEROQUEL [see Clinical Studies (14.1) ]. 1.2 Bipolar Disorder SEROQUEL XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of SEROQUEL XR in manic or mixed episodes of bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10 - 17 years) with manic episodes associated with bipolar I disorder treated with SEROQUEL [see Clinical Studies (14.2) ]. SEROQUEL XR is indicated for the acute treatment of depressive episodes associated with bipolar disorder. The efficacy of SEROQUEL XR was established in one 8-week trial in adults with bipolar I or II disorder and supported by two 8-week trials in adults with bipolar I or II disorder treated with SEROQUEL [see Clinical Studies (14.2) ]. SEROQUEL XR is indicated for the maintenance...
Mechanism: The mechanism of action of quetiapine in the listed indications is unclear. However, the efficacy of quetiapine in these indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2A (5HT 2A ) antagonism. The active metabolite, N-desalkyl quetiapine (norquetiapine), has similar activity at D 2 , but greater activity at 5HT 2A receptors, than the parent drug (quetiapine).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 30, 2013 Supplement 29 · Efficacy LabelLetter
- Dec 2, 2009 Supplement 11 · Efficacy LabelReviewLetter
- Oct 8, 2008 Supplement 8 · Efficacy LabelLetter
- Oct 8, 2008 Supplement 6 · Efficacy LetterLabel
- Oct 8, 2008 Supplement 7 · Efficacy LabelLetter
- May 17, 2007 Original approval · Type 3 - New Dosage Form Other Important Information from FDALetterReview
5 products under this application
- SEROQUEL XR · QUETIAPINE FUMARATE EQ 400MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- SEROQUEL XR · QUETIAPINE FUMARATE EQ 200MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- SEROQUEL XR · QUETIAPINE FUMARATE EQ 150MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- SEROQUEL XR · QUETIAPINE FUMARATE EQ 300MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- SEROQUEL XR · QUETIAPINE FUMARATE EQ 50MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Quetiapine" as an intervention, any sponsor and status, largest first.
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT05480150 · 10,000 participants (planned) · Start Nov 1, 2021 · Primary completion Dec 31, 2026
Drug: Escitalopram Oxalate Tablets; Quetiapine Fumarate Tablets and 1 more · For: Major Depressive Disorder; Bipolar Disorder, Mixed; Affective; Disorder, Organic
Sites: Hangzhou, China
- Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive DisorderPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00278941 · 3,000 participants · Start Dec 2005
Drug: Quetiapine Fumarate Sustained Release · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Mesa, Arizona · 168 sites in all
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01727726 · 2,182 participants · Start Dec 2012 · Primary completion Oct 17, 2016
Drug: Brexpiprazole; Seroquel XR and 1 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 76 sites in all
- Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major DepressionPivotal-lookingCompleted
University of SaskatchewanAcademic, hospital or other
NCT03207438 · 1,790 participants · Start Apr 2006 · Primary completion Jul 2007
Drug: Quetiapine 50 MG Extended Release Oral Tablet; Quetiapine Fumarate XR 150-300 mg and 1 more · For: Depressive Disorder, Major
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
- Quetiapine Fumarate Bipolar Maintenance MonotherapyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00314184 · 1,255 participants · Start Mar 2005
Drug: quetiapine fumarate · For: Bipolar Disorder
Sites: Cerritos, California; San Diego, California; Santa Ana, California · 95 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective9,887
- off label use9,865
- insomnia8,363
- toxicity to various agents8,318
- diabetes mellitus8,095
- somnolence7,358
- fatigue7,022
- drug interaction6,787
- weight increased6,710
- anxiety6,689
- nausea6,604
- depression6,467
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,549 |
| 2005 | 1,921 |
| 2006 | 3,134 |
| 2007 | 5,530 |
| 2008 | 3,326 |
| 2009 | 7,688 |
| 2010 | 9,164 |
| 2011 | 10,170 |
| 2012 | 10,999 |
| 2013 | 4,481 |
| 2014 | 5,545 |
| 2015 | 7,047 |
| 2016 | 6,970 |
| 2017 | 8,436 |
| 2018 | 9,760 |
| 2019 | 10,016 |
| 2020 | 10,161 |
| 2021 | 9,134 |
| 2022 | 8,643 |
| 2023 | 8,868 |
| 2024 | 8,920 |
| 2025 | 8,430 |
| 2026 | 6,387 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Seroquel XR (Quetiapine Fumarate)
2024 spending
$7.5M
Beneficiaries
951
7,036 claims
Per beneficiary
$7,869
$18.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,776,733 |
| 2021 | $12,146,599 |
| 2022 | $10,819,557 |
| 2023 | $9,338,118 |
| 2024 | $7,483,539 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials.
Lin CY, Chiang CH, Tseng MM, et al. · Eur Neuropsychopharmacol 2023 · Meta-Analysis, Systematic Review
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.
McIntyre RS, Stahl SM, Shim SR, et al. · JAMA Psychiatry 2026 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Yildiz A, Siafis S, Mavridis D, et al. · Lancet Psychiatry 2023 · Systematic Review, Network Meta-Analysis
Sponsor: Cheplapharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.